
Biogen Idec Inc.and Bayer AG would have to cut the price of their multiple sclerosis drugs by at least two-thirds in the U.S. to make them cost effective at boosting quality of life, a study found.
Disease-modifying drugs for MS like Avonex from Weston, Massachusetts-based Biogen, and Betaseron, sold by Leverkusen, Germany-based Bayer, are at least eight times costlier than what researchers consider reasonable when putting a price on quality- of-life improvement, according to the study published today in the journal Neurology. The study also found that prescribing the drugs in earlier stages of MS improved cost effectiveness.
Multiple sclerosis affects about 400,000 people in the U.S., and 2.5 million worldwide, according to the National Multiple Sclerosis Society. The chronic disease attacks the central nervous system and can cause paralysis, numbness in limbs and vision loss. The disease-modifying drugs, which delay progression and reduce relapse of MS, can cost about $34,000 a year in the U.S., compared with about 8,000 pounds ($12,920) in the U.K., the study said. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1809